Status:
UNKNOWN
Micro-wave Ablation Under Organ-based Tracking in Patients With Prostate Cancer - FOSTINE
Lead Sponsor:
Jules Bordet Institute
Collaborating Sponsors:
Koelis
Conditions:
Focal Treatment for Prostate Cancer
Eligibility:
MALE
45-76 years
Phase:
NA
Brief Summary
With the advent of multiparametric MRI (mpMRI), the concept of focal therapy continues to develop as a compromise between active surveillance and radical tratment. However, it must be combined with th...
Detailed Description
Patients with a detectable index lesion on mpMRI, PSA level \<20 ng/mL and wishing to undergo a prostatectomy due to significant PCa on biopsy are elibible for this study approved by the Ethics Commit...
Eligibility Criteria
Inclusion
- Patients with detectable index lesion on mpMRI, PSA level \<20 ng/mL and wishing to undergo a prostatectomy due to significant PCA on biopsy.
- Life expectancy up to 10 years or plus.
Exclusion
- Past history of prostate surgery or pelvic radiotherapy, prostatitis, extra-capsular extension on MRI or index lesion above 25 mm, distance between rectum and index lesion less than 5 mm.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04831905
Start Date
March 1 2021
End Date
May 1 2021
Last Update
April 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Jules Bordet
Brussels, Belgium, 1000